[go: up one dir, main page]

WO2000066174A3 - Compounds - Google Patents

Compounds Download PDF

Info

Publication number
WO2000066174A3
WO2000066174A3 PCT/IE2000/000041 IE0000041W WO0066174A3 WO 2000066174 A3 WO2000066174 A3 WO 2000066174A3 IE 0000041 W IE0000041 W IE 0000041W WO 0066174 A3 WO0066174 A3 WO 0066174A3
Authority
WO
WIPO (PCT)
Prior art keywords
adduct
ranitidine
clarithromycin
base
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IE2000/000041
Other languages
French (fr)
Other versions
WO2000066174A2 (en
Inventor
Helmut Schickaneder
Aggelos Kikolopoulos
Gesine Hermann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Russinsky Ltd
Original Assignee
Russinsky Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Russinsky Ltd filed Critical Russinsky Ltd
Priority to AU36680/00A priority Critical patent/AU3668000A/en
Publication of WO2000066174A2 publication Critical patent/WO2000066174A2/en
Publication of WO2000066174A3 publication Critical patent/WO2000066174A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/552—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being an antibiotic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

An adduct contains Clarithromycin and Ranitidine either in the form of a base or a base hydrate in which the molar ratio of Clarithromycin to Ranitidine in the adduct is at least 2:1. The adduct has high stability and is particularly useful in a single dose formulation for the treatment of gastrointestinal disorders.
PCT/IE2000/000041 1999-04-29 2000-04-04 Compounds Ceased WO2000066174A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU36680/00A AU3668000A (en) 1999-04-29 2000-04-04 Compounds

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IE990357 1999-04-29
IE990357 1999-04-29
IE990993 1999-11-29
IE990993 1999-11-29

Publications (2)

Publication Number Publication Date
WO2000066174A2 WO2000066174A2 (en) 2000-11-09
WO2000066174A3 true WO2000066174A3 (en) 2001-03-15

Family

ID=26320246

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IE2000/000041 Ceased WO2000066174A2 (en) 1999-04-29 2000-04-04 Compounds

Country Status (2)

Country Link
AU (1) AU3668000A (en)
WO (1) WO2000066174A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0533281A1 (en) * 1991-09-20 1993-03-24 Glaxo Group Limited The use of ranitidine bismuth citrate and one or more heliocobacte pylon-inhibiting antibiotics with manufacture of a medicament for treating gastrointestinal disorders
WO1998056357A1 (en) * 1995-12-19 1998-12-17 Abbott Laboratories A controlled release formulation for poorly soluble basic drugs
WO1999065890A1 (en) * 1998-06-17 1999-12-23 Russinsky Limited Ranitidine adduct

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0533281A1 (en) * 1991-09-20 1993-03-24 Glaxo Group Limited The use of ranitidine bismuth citrate and one or more heliocobacte pylon-inhibiting antibiotics with manufacture of a medicament for treating gastrointestinal disorders
WO1998056357A1 (en) * 1995-12-19 1998-12-17 Abbott Laboratories A controlled release formulation for poorly soluble basic drugs
WO1999065890A1 (en) * 1998-06-17 1999-12-23 Russinsky Limited Ranitidine adduct

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FROTZ H ET AL: "[ Ranitidine and clarithromycin for eradication of Helicobacter pylori in patients with duodenal ulcer]. Ranitidin und Clarithromycin zur Eradikation von Helicobacter pylori bei Patienten mit Ulcus duodeni.", ARZNEIMITTEL-FORSCHUNG, (1995 FEB) 45 (2) 184-6., XP002155014 *

Also Published As

Publication number Publication date
IE20000248A1 (en) 2000-11-29
AU3668000A (en) 2000-11-17
WO2000066174A2 (en) 2000-11-09

Similar Documents

Publication Publication Date Title
CA2334875A1 (en) Composition for the prevention and/or treatment of osteoporosis and alterations due to menopause syndrome
BE2011C028I2 (en) Macrocyclic analogs and methods of their use and preparation
CA2295035A1 (en) Pharmaceutical formulations containing voriconazole
CA2182582A1 (en) Compositions containing micronized nebivolol
WO2003013541A8 (en) 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives
EP2322187A3 (en) Use of uridine in combination with choline for the treatment of memory disorders
HUP0101158A3 (en) Use of glycogen phosphorylase inhibitors for the preparation of pharmaceutical compositions for the prophylactic treatment of type 2 diabetes mellitus
CA2326756A1 (en) Pharmaceutical compositions containing compounds with activity for the enhancement of absorption of active ingredients
YU69603A (en) Atorvastatin calcium in a pharmaceutical form, composition thereof, and pharmaceutical formulation comprising atorvastatin calcium
CA2327723A1 (en) Bicyclic hydroxamic acid derivatives
WO2002000209A3 (en) Gabapentin analogues for sleep disorders
ZA200300712B (en) Pharmaceutical compositions for the treatment of mucositis, stomatitis and Behcet's syndrome.
WO2000066104A3 (en) Ace-2 inhibiting compounds and methods of use thereof
CA2270177A1 (en) Transdermal administration of ment
AU2002309038A1 (en) Compositions for transmucosal administration containing coenzyme Q as the active ingredient
AP2004003045A0 (en) Preparation compositions containing acid-unstable physiologically active compounds and process for producing the same.
WO2000072820A3 (en) Injectable anesthetic formulation
WO1999061010A3 (en) Treatment of infertility with cam-increasing compounds alone or in combination with at least one meiosis-stimulating compound
WO2000054780A3 (en) Corticosteroid formulation
CA2114859A1 (en) Cytotoxic and antiviral compound
AU1650501A (en) 1,3,4-oxadiazoline derivatives and drugs containing these derivatives as the active ingredient
CA2399709A1 (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid and/or physiologically compatible salts thereof for producing a medicament for treating cancers
WO2000066174A3 (en) Compounds
WO1999056697A3 (en) Pharmaceutical composition
WO2001046178A3 (en) Substituierte bisindolymaleimide

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP